US20050273033A1 - Shunt and method treatment of glaucoma - Google Patents
Shunt and method treatment of glaucoma Download PDFInfo
- Publication number
- US20050273033A1 US20050273033A1 US10/515,999 US51599905A US2005273033A1 US 20050273033 A1 US20050273033 A1 US 20050273033A1 US 51599905 A US51599905 A US 51599905A US 2005273033 A1 US2005273033 A1 US 2005273033A1
- Authority
- US
- United States
- Prior art keywords
- tube
- shunt
- frontal sinus
- anterior chamber
- valve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0612—Eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
Definitions
- the present invention relates to a method and device for controlling aqueous humor flow from the anterior chamber of the eye in the treatment of glaucoma.
- Glaucoma is a medical condition in which the intraocular pressure of the eye increases.
- the anterior chamber the cavity located between the cornea and lens, is filled with a fluid called aqueous humor.
- the aqueous humor drains from the anterior chamber to the venous system through the canals of Schlemm and is replaced continuously by secretions from the ciliary body.
- Glaucoma occurs when aqueous humor does not drain properly from the anterior chamber, causing an increase in intraocular pressure, closure of surrounding blood vessels, and damage to the retina and optic nerve.
- This condition left untreated, can be very painful and lead to blindness. It is estimated that 65 million people world-wide suffer from this condition (Glaucoma Research Foundation, 2002). Animals can also be affected by this condition. It is estimated there are 65 million dogs in North America, of which approximately 1.3 million will develop glaucoma.
- Closed-angle glaucoma occurs when the iris becomes misshapen and blocks the canals of Schlemm.
- the underlying cause of open-angle glaucoma is a blockage within the canals.
- About 3 million people in the United States are afflicted with open-angle glaucoma (Glaucoma Research Foundation, 2002).
- Secondary glaucoma either open- or closed-angle, can be caused by injury, abnormal structures, inflammation, tumours, certain drugs, or diseases (Moffett et al, 1993).
- Implants have also been used in the treatment of glaucoma. These implants drain aqueous humor from the anterior chamber into mesenchymal or subconjunctival tissues surrounding the eye.
- the aqueous humor of eyes afflicted with glaucoma has a relatively high concentration of cytokines. Cytokines are proteins that mediate the generation of an immune response. Implants that drain aqueous humor into tissues surrounding the eye induce scarring in such tissues, which scarring ultimately inhibits absorption of fluid from the shunt. Consequently glaucoma recrudesces and visual impairment redevelops.
- Non-restrictive flow devices such as the Molteno drainage implant, rely on the formation of fibrous tissue to slow the drainage of fluid from the eye. These implants require at least two invasive surgical procedures. The initial surgery is required to implant the device. Fibrous tissue generally takes several weeks to form, making it necessary to clamp or tie the device to limit fluid drainage and prevent hypotony. A second surgery is required to unclamp or untie the device once fibrosis has occurred.
- Restrictive flow devices such as the Krupin Eye Disk, are designed with components that respond to fluid pressure, see for example U.S. Pat. No. 5,454,796, issued Oct. 3, 1995 to Krupin, and U.S. Design Pat.
- the frontal sinus 16 is an epithelium-lined cavity which is not affected by cytokines. Studies by Cullen et al., with a shunt implanted in dogs between the anterior chamber and the frontal sinus showed no evidence of bacterial movement from the frontal sinus 16 to the eye through this device (see Cullen et al, 1998).
- the inventors have developed a shunt device and method of treatment for glaucoma that diverts aqueous humor from the anterior chamber to an epithelial-lined space. While the method and device have been successfully demonstrated with dogs, in which the shunt was implanted between the anterior chamber of the eye and the frontal sinus, the invention has application for the treatment of glaucoma in all species of animals, including humans, and to other epithelial-lined spaces besides the frontal sinus.
- epithelial-lined space includes epithelial and epithelial-lined spaces, including the frontal sinus, maxillary sinus, nasal sinus, other respiratory sinuses or spaces, subdural space, and meningeal cavity.
- the invention provides a shunt for implantation between the anterior chamber of the eye and the epithelial-lined space through the frontal sinus bone of a patient for the treatment of glaucoma.
- the shunt includes a tube having a length sufficient to span the distance between the anterior chamber of the eye and the epithelial-lined space of the patient, the tube having an open anterior chamber end and a closed epithelial-lined space end, and a seal device associated with the tube between the anterior chamber and epithelial-lined space ends, for sealing a hole in the frontal sinus bone, and for anchoring the tube against movement from the frontal sinus bone.
- the shunt also includes a fluid pressure openable valve in the tube, located at or near the epithelial-lined space sinus end, allowing for controlled flow of aqueous humor through the tube when implanted.
- the invention also broadly provides a method of treating glaucoma in a patient, comprising (a) forming a hole from the exterior into the epithelial-lined space, for example in the frontal sinus bone, of the patient; (b) surgically implanting through the hole, between the anterior chamber and the epithelial-lined space, a shunt having a fluid pressure openable valve; and (c) draining aqueous humor from the anterior chamber through the shunt to the epithelial-lined space.
- the shunt preferably includes a tube having an open anterior chamber end and a closed epithelial-lined space end, and wherein the valve is located at the frontal sinus end, allowing for controlled flow of aqueous humor through the tube when implanted.
- FIG. 1 illustrates the shunt of the present invention implanted in a dog, with portions of the eye being cut away to illustrate placement of the shunt between the anterior chamber and the frontal sinus;
- FIG. 2 is a sectional view of the shunt implanted in the eye, better illustrating the anterior chamber placement.
- FIG. 3 is a sectional view of the shunt threaded through the anchoring sealing device.
- FIG. 4 is a sectional view of the shunt showing the anchoring sealing device in place in the hole in the frontal sinus bone.
- FIG. 5 is a partial perspective view of the shunt showing the slit valve and the ligatures used to adjust and control flow of aqueous humor through the valve.
- FIG. 6 is a schematic side sectional view of a second embodiment of a shunt of the present invention, illustrating a drainage reservoir housing for alternate valve devices.
- FIG. 7 is an a schematic side sectional view of a third embodiment of a shunt of the present invention, illustrating a drainage reservoir for housing alternate valve devices, which drainage reservoir also functions as the sealing device.
- FIG. 8 is a perspective view, partially cut-away, showing a tapered nipple plug type valve within the reservoir chamber of either FIGS. 7 and 8 .
- FIG. 9 is a perspective view, partially cut-away, showing the tapered nipple plug valve of FIG. 8 in the open position.
- FIG. 10 is a perspective view of the taper nipple plug valve unit of FIGS. 8 and 9 .
- the shunt of the present invention shown generally at 10 in the Figures is shown as designed for implantation between the anterior chamber and the frontal sinus, however, the shunt has application for implantation to other epithelial-lined spaces, including the maxillary sinus, nasal sinus, other respiratory sinuses or spaces, subdural space, and meningeal cavity.
- the details of a first embodiment of the shunt 10 are best shown in FIGS. 3-5 , while the placement of the shunt 10 in a dog is shown in FIGS. 1 and 2 .
- the shunt 10 consists of a tube 12 , made of a biocompatible material such as silicone.
- the length of the tube required is dependent on the species, but is of sufficient length to reach the distance between the anterior chamber 14 and the frontal sinus 16 , through the frontal sinus bone 18 , of the given animal species.
- the tube 12 thus has a frontal sinus end 20 and an anterior chamber end 22 .
- the tube 12 is threaded through a sutureless sealing device 24 , which seals around the hole 25 in the frontal sinus bone 18 .
- the sealing device 24 is located close to the frontal sinus end 20 of the tube 12 . This acts to hold the tube 12 in place as well as prevents it from kinking.
- a valve device 26 is provided at or near the frontal sinus end 20 of the tube 12 (i.e., when implanted the valve is on the sinus side of the frontal sinus bone). The sealing device 24 also functions to prevent serum and clots from exuding from the exposed bone 18 and from subcutaneous tissues within the frontal sinus and into the valve device 26 .
- the valve device 26 is shown to be of a slit valve type, formed by constructing a slit 28 in the frontal sinus end 20 of the tube 12 approximately parallel to the longitudinal axis of the tube 12 .
- This frontal sinus end 20 is inserted into the frontal sinus 16 and held in place with the sealing component 24 , which straddles the frontal sinus bone 18 and anchors the tube against movement in either direction.
- the tube 12 is then tunnelled subcutaneously towards the eye and into the anterior chamber 14 . Surgical implantation of the shunt 10 is more fully explained below.
- the shunt will generally have a length ranging from 30 to 150 mm, and may be trimmed to length during surgery. However, the shunt can be made to fit any species of animal (including humans) by trimming any excess length from the anterior chamber end 22 .
- the shunt is generally formed from flexible, biocompatible materials such as silicone, glass, medical grade acrylics, plastic, or metal manufactured parts, with silicone or any similar biocompatible, flexible material being most preferred.
- One advantage of the present invention is that the tube 12 of the shunt 10 can be formed from tubing having internal and external diameters that can be varied according to the patient species together with the surgeon's preference and/or the surgeon's skill. The dimensions are affected by the space available in a particular patient's eye between the cornea and the lens.
- the tube 12 should be sized so as to be fitted into such space in such a fashion that the anterior chamber end 22 does not contact the iris, lens or cornea.
- exemplary dimensions for the shunt of the present invention for implantation in dogs are as follows.
- flexible tubing such as silastic tubing
- ranging from 0.25 to 0.64 mm inner diameters and 0.6 to 0.14 mm outer diameters with a wall thickness from 0.2 to 0.64 mm are optimal.
- the method and shunt 10 of the present invention allows for the control of aqueous humor flow from the valve device 26 by means of a simple adjustment procedure, explained more fully below.
- a major constraint of prior art glaucoma shunts, the control of intraocular pressure via fluid flow from valves, is addressed with the present invention in that the flow of aqueous humor is controlled by using an adjustable valve, or by associating a flow control device with a valve.
- flow adjustment through the slit 28 is provided by means of one or more ligature devices 30 .
- the ligature devices 30 may be formed from O-rings, D-rings, C-clamps, sutures, or circumferential sutures formed of a biocompatible material, which are placed or tied around the tube 12 over and/or adjacent the slit 28 . These ligature devices 30 tighten the slit 28 , allowing less fluid to escape from the tube 12 and drain from the anterior chamber 14 .
- the addition or removal of these ligature devices 30 to control flow can be made by a simple skin incision above the frontal sinus 16 , which also allows for easy removal of the shunt 10 (more fully described below). Hydrostatic pressures of aqueous humor of glaucoma-affected patients can vary among species and idiotypically among patients. Also, rates of aqueous fluid of different species vary significantly.
- the easy adjustment of the valve device 26 allows this shunt 10 to be used in the treatment of various species, as well as each individual within a species.
- the slit 28 will generally be about 0.5 to 2.0 mm long, and oriented approximately parallel to the longitudinal axis of the tube 12 .
- the slit 28 is preferably perpendicular to the tangent of the tube wall. Variability in the length of the slit, the number of slits, the number of ligature devices and the positioning of ligature devices in relation to the slit provides flexibility sufficient to permit adjustment for use with various species, as well as various hydrostatic pressures of aqueous humor.
- the ligature devices 30 around the tube 12 are mounted circumferentially around the longitudinal axis of the slit 28 and snug enough to slightly indent the tube 12 without disturbing the orientation of the slit.
- the ligature devices 30 are formed of a biocompatible material, with metal C-shaped clamps, and plastic, silicone, or rubber round O-rings, being most preferred. These preferred ligature devices are less prone to surgeon error than sutures in that they can be sized such that they do not excessively compress the valve walls and can be pre-placed at one or both ends of the slit 28 .
- these ligature devices 30 are slidably moved into variable positions along the length of the slit 28 , and the intraocular pressure (fluid pressure indicative of glaucoma operative to open valve) is measured to ensure a desired intraocular pressure will open the valve device 26 .
- Multiple ligature devices, up to 3/mm, have been found to provide flexibility that allows the surgeon to finely adjust valve tension and aqueous flow rates through the valve device 26 .
- the sealing device 24 can take a variety of forms, such as a widened portion (not shown) of the tube 12 , a widened reservoir plug as shown in FIG. 7 , or a spool-shaped plug type seal as shown in FIGS. 3 and 4 . It is functional to seal the shunt 10 against the hole 25 in the frontal sinus bone 18 , and to anchor the shunt against movement relative to the bone 18 once implanted. The sealing device also bends the tube 12 though an angle sufficient to ensure that the valve device 26 , when the shunt 10 is implanted, is wholly within the frontal sinus and maintained in the space (not abutting the frontal sinus epithelium.
- an bending angle of 80 to 100° is desired, so as to maintain the most desired ingress and egress angle of the shunt between the frontal sinus 16 and the anterior chamber 14 .
- an angle of about 90° was used.
- the sealing device is most preferably a molded, spool-shaped (grommet-like) plug 32 , attached to the tube 12 and having an central bore 34 sized to fit snugly around the tube 12 .
- the plug may be manufactured by carving a wax or wooden mold, positioning the tube 12 in the mold at the desired ingress and egress angles, flooding the mold with liquid silicone, allowing it to set and removing the plug from the mold.
- the plug 32 has a central portion 36 joined to and an upper flange or lip (anterior chamber facing) 38 and a lower flange or lip (frontal sinus facing) 40 .
- the flanges 38 , 40 have a widened diameter relative to the diameter of the central portion 36 .
- Biocompatible materials for the plug are silicone (a preferred embodiment) and rubber, plastic, glass, or metal components.
- At least the lower flange 40 which is frontal sinus facing, is made of a viscoelastic material such as silicone, to enable it to be compressed and forced through the hole 25 in the sinus bone 18 .
- the plug 32 bends the tube 12 though about an 80 to 100° angle.
- the shunt 10 should enter the anterior chamber 10-25 degrees anterior to the limbal plane to avoid contact with the iris, crystalline lens, or corneal endothelium.
- the trephine hole 25 of the frontal sinus 16 is best situated approximately perpendicular to the frontal bone 18 .
- the tube 12 should enter and leave the at plug 32 at about 90° (i.e., bend the tube through about 90°), but curve gently within the central bore 34 of the plug 32 , to decrease the potential for occlusion of the shunt 10 by kinking the tube 12 or allowing trapping of fibrin clots within this turn of the tube 12 .
- the frontal sinus plug 32 should be compressible to allow the lower flange 40 , having a diameter slightly larger than the trephined hole 25 , to be introduced into the frontal sinus (preventing unintentional egression of the shunt 10 ), and providing pressure against the bony walls of the trephined hole 25 to stop hemorrhage from the bone 18 and to stop fibrin and blood from collecting around the valve device 26 .
- the center portion 36 has a diameter of about 0.25-1.5 mm, which is approximately equal to the bore dimensions of the trephined hole 25 , and approximately 0.1 mm shorter than the thickness of the bone 18 (1-2.5 mm), to create a tight sealing fit to prevent haemorrhage from the bone 18 that may drain onto the valve device 26 .
- the external diameter of the flanges 38 , 40 are about 0.1-0.6 mm greater than the outside diameter of the tube 12 , and at least twice the diameter of the trephined hole 25 to prevent complete ingress into the frontal sinus 16 .
- the shunt of the present invention are formed from biocompatible materials, that is materials which are biologically non-reactive and non-toxic to the patient.
- biocompatible materials that is materials which are biologically non-reactive and non-toxic to the patient. Examples are silicone (sialastic tubing), glass, medical grade plastic and some metals.
- FIGS. 6-10 Second and third embodiments of the shunt 10 are shown in FIGS. 6-10 .
- the valve device 26 is shown to include a drainage reservoir 42 housing a valve element (not shown).
- the drainage reservoir 42 is shown to also function as the sealing device 24 in the frontal bone 18 .
- a variety of check valve types may be incorporated in these embodiments, such as the nipple plug type valve shown in FIGS. 7-10 , or a butterfly valve (not shown).
- the reservoir 42 is shown in the figures to be formed from an apertured upper plate 44 , a closed bottom plate 46 , connected together by a side wall 48 which includes perforations such as longitudinal slits 50 which allow fluid to drain from the reservoir 42 .
- FIG. 6 the valve device 26 is shown to include a drainage reservoir 42 housing a valve element (not shown).
- FIG. 7 the drainage reservoir 42 is shown to also function as the sealing device 24 in the frontal bone 18 .
- a variety of check valve types may be incorporated in these embodiments, such
- the reservoir 42 is shown to include a widened sealing flange 52 , to seal and anchor against the frontal sinus bone 18 .
- the nipple plug type valve components are best shown in FIG. 10 , to include an upper orifice plate 54 and a lower nipple plug 56 operative to seal in the orifice plate 54 .
- the plate 54 and plug 56 are joined together in a normally closed position (shown in FIG. 8 ), by a spring member 58 , having a tension such that the valve is fluid openable under predetermined pressures associated with glaucoma to allow fluid to flow through the orifice plate 54 and out the perforations 50 .
- the nippled plug 56 will reseal against the orifice plate 54 .
- Surgical implantation of the shunt 10 in accordance with the present invention is described below, following aseptic preparation of the surgical field including the eye and skin of the patient and positioning the patient under an operating microscope.
- Over the ipsilateral frontal bone the skin, subcutaneous tissues, and muscle over the zygomatic process of the frontal bone are incised.
- the incision should be long enough to expose the frontal bone over the frontal sinus (typically approx 1′′ long and oriented rostrocaudally.
- the location of the frontal sinus 16 can be confirmed by tapping the frontal bone of the zygomatic process with a solid object (such as a surgical instrument) to confirm a hollow sound.
- a drilling device (such as a Jacob's chuck and Steinmann's pin—not shown), sized appropriately for the patient, is employed to make the hole 25 in the bone 18 over the frontal sinus 16 , into the frontal sinus 16 from the exterior.
- the size of the hole 25 will vary with patient and species, and is matched to the size of the sealing device 24 .
- the sinus is visualized as a white cavity.
- Patency of the shunt 10 is confirmed by (i) cannulating the shunt (anterior chamber end 22 ) with a aqueous-fluid-filled syringe and needle (typically 27-30 ga.) assembly—not shown; (ii) flushing the aqueous fluid (e.g. sterile balanced slat solution) through the shunt 10 under pressure from the syringe; and (iii) visualizing fluid passing through the valve device 26 .
- aqueous fluid e.g. sterile balanced slat solution
- the frontal sinus end 20 of the shunt 10 is placed within the trephined hole 25 of the sinus and can be held in place by slight compression of the sealing device 24 and by the upper and lower flanges 38 , 40 .
- An eyelid speculum is then placed ipsilaterally on the eyelids to expose the conjunctival surface.
- a conjunctival incision is made from the limbus (junction of cornea, schlera, and conjuctiva) to the formix (reflexion of the conjuctiva under the eyelid) and extended through to the epischlera.
- An instrument such as pair of small forceps, not shown, is used to bluntly dissect a tunnel from the conjunctival incision to the frontal sinus incision (typically over the dorsal rim of the orbit to the original surgical dissection exposing the frontal sinus).
- the tip of such instrument can be visualized it can be used to grasp the free end (anterior chamber end 22 ) of the shunt.
- the shunt 10 is then drawn back through the tunnel through the conjunctival incision.
- the shunt 10 is layed across the surface of the cornea and the length of the shunt is trimmed so as to adjust its length such that is rests approximately 1/4 of the vertical length of the anterior chamber 14 .
- the anterior chamber end 22 of the shunt is trimmed obliquely at 45 to 60 degrees with the bevel opening anteriorly.
- a cutting device e.g., 20 gauge disposable stilleto blade, not shown
- the angle at which the blade enters the anterior chamber should be approximately 20° (the shunt 10 should enter the anterior chamber 14 at 10-25° anterior to the limbal plane to ensure that the shunt is positioned equal distance between the iris and the cornea to avoid contact between the shunt and the iris, crystal lens, or corneal endothelium).
- Small forceps e.g. tying forceps
- tying forceps are used to grasp the anterior chamber end 22 of the shunt near the bevelled end, and the shunt 10 is inserted into the anterior chamber 14 .
- the shunt 10 is anchored to the sclera with, for example, nonabsorbable (monofilament) more than one (usually to or maximally (practically) three) sutures in a simple interrupted pattern.
- the Tenon's capsule and conjunctiva are closed with, for example, simple interrupted sutures of small (7-0 to 10-0) monofilament absorbable sutures.
- the frontal sinus end 20 of the shunt is withdrawn from the frontal sinus 16 and monitored for flow of aqueous humor through the valve device 26 .
- fluid flow through the valve device 26 is confirmed, such flow is adjusted at the valve device 26 .
- the flow is adjusted with at least one ligature device 30 around or adjacent the slit 28 to maintain a desired intraocular pressure, which can be measured at the corneal surface with an applanation tonometer in the O.R. (normal for dog approximately 18 mm Hg).
- the valve device 26 is adjusted to open above this predetermined and known fluid pressure associated with glaucoma.
- the predetermined fluid pressure associated with glaucoma is known for other species, and the valve device can be adjusted accordingly for other species.
- the frontal sinus end 20 of the shunt 10 is then replaced into the frontal sinus 16 .
- Subcutaneous tissues are closed with, for example, small (3-0 to 6-0) monofilament absorbable sutures in a simple continuous pattern.
- the skin is subsequently closed with, for example, small (3-0 to 5-0) monofilament nonabsorbable suture in a simple interrupted pattern.
- the shunt 10 of this invention can be flushed through the valve device 26 by incising the skin, removing the frontal sinus end 20 , and back flushing an antifibrinolytic compound (e.g. tissue plasminogen activator (TPA)) retrograde through the shunt.
- TPA tissue plasminogen activator
- Subsequent flushing of the shunt 10 with TPA or saline in the event of occlusion of the shunt is accomplished by exposing the frontal sinus end 20 of the shunt 10 , removing it from the sinus 16 , and flushing the shunt retrograde.
- TPA tissue plasminogen activator
- the frontal sinus end 20 of the shunt 10 can be exposed and ligatures placed at various intervals along the slit 28 to attain the desired intraocular pressure.
- a shunt of the present invention was designed for and successfully implanted into four dogs having glaucoma.
- the details of the implanted shunt were as follows:
- the method and shunt of the present invention allows the correction to be made by a simple skin incision above the frontal sinus.
- the sealing device 24 and anterior chamber end 22 of the tube 12 are removed from the frontal sinus 16 , flushed with sterile fluid, and reinserted. Further cleanings are not normally required.
- the fibrous tissue that collects around the shunt once implanted forms a tunnel from the sinus incision to the anterior chamber 14 . If the shunt 10 needs to be replaced, the original can be removed through the sinus incision and a new device inserted through the tunnel created by the fibrous tissue. An extensive surgery is not required.
Abstract
Description
- The present invention relates to a method and device for controlling aqueous humor flow from the anterior chamber of the eye in the treatment of glaucoma.
- Glaucoma is a medical condition in which the intraocular pressure of the eye increases. The anterior chamber, the cavity located between the cornea and lens, is filled with a fluid called aqueous humor. The aqueous humor drains from the anterior chamber to the venous system through the canals of Schlemm and is replaced continuously by secretions from the ciliary body. Glaucoma occurs when aqueous humor does not drain properly from the anterior chamber, causing an increase in intraocular pressure, closure of surrounding blood vessels, and damage to the retina and optic nerve. This condition, left untreated, can be very painful and lead to blindness. It is estimated that 65 million people world-wide suffer from this condition (Glaucoma Research Foundation, 2002). Animals can also be affected by this condition. It is estimated there are 65 million dogs in North America, of which approximately 1.3 million will develop glaucoma.
- Closed-angle glaucoma occurs when the iris becomes misshapen and blocks the canals of Schlemm. The underlying cause of open-angle glaucoma is a blockage within the canals. About 3 million people in the United States are afflicted with open-angle glaucoma (Glaucoma Research Foundation, 2002). Secondary glaucoma, either open- or closed-angle, can be caused by injury, abnormal structures, inflammation, tumours, certain drugs, or diseases (Moffett et al, 1993).
- Current treatments consist of medications, laser surgery and implantable drainage devices (Glaucoma Research Foundation, 2002). Medications, often in the form of eye drops, work to decrease intraocular fluid production, increase fluid drainage, or both. These medications are associated with side effects, including burning sensations in the eye, headaches, cardiac fluctuations and blurred vision. The administration of medications for the treatment of animals is difficult and ineffective. Laser surgery is used to open the fluid draining channels or correct structures in the eye. Multiple surgeries are often required, and medication is normally still used to help control intraocular pressure post-surgery. There is also the risk of allowing too much fluid to drain from the anterior chamber, resulting in hypotony and flattening of the eye.
- Implants have also been used in the treatment of glaucoma. These implants drain aqueous humor from the anterior chamber into mesenchymal or subconjunctival tissues surrounding the eye. The aqueous humor of eyes afflicted with glaucoma has a relatively high concentration of cytokines. Cytokines are proteins that mediate the generation of an immune response. Implants that drain aqueous humor into tissues surrounding the eye induce scarring in such tissues, which scarring ultimately inhibits absorption of fluid from the shunt. Consequently glaucoma recrudesces and visual impairment redevelops.
- Current drainage implants are classified as either restrictive or non-restrictive flow devices (Gal, 1999). Non-restrictive flow devices, such as the Molteno drainage implant, rely on the formation of fibrous tissue to slow the drainage of fluid from the eye. These implants require at least two invasive surgical procedures. The initial surgery is required to implant the device. Fibrous tissue generally takes several weeks to form, making it necessary to clamp or tie the device to limit fluid drainage and prevent hypotony. A second surgery is required to unclamp or untie the device once fibrosis has occurred. Restrictive flow devices, such as the Krupin Eye Disk, are designed with components that respond to fluid pressure, see for example U.S. Pat. No. 5,454,796, issued Oct. 3, 1995 to Krupin, and U.S. Design Pat. Des. 356,867 issued Mar. 28, 1995 to Krupin. When pressure in the drainage tube exceeds a certain limit, the component, or valve, will open and allow fluid to drain. Several problems have occurred with these devices. First, it is difficult to calibrate the valve to maintain an optimal intraocular pressure, and often leads to hypotony. Second, the formation of fibrous tissue can occlude the valve and render the drainage device useless. A similar restrictive flow device is disclosed in U.S. Pat. Nos. 6,142,969 and 6,007,510, issued to Nigam.
- The
frontal sinus 16 is an epithelium-lined cavity which is not affected by cytokines. Studies by Cullen et al., with a shunt implanted in dogs between the anterior chamber and the frontal sinus showed no evidence of bacterial movement from thefrontal sinus 16 to the eye through this device (see Cullen et al, 1998). - Although somewhat successful in less severe cases, the prior art implant devices, while successful in the short term, are not effective for long-term management of glaucoma due to occurrence of hypotony or more difficult forms of glaucoma. More effective treatment regimes are needed.
- To overcome the difficulties induced by fibrosis blocking the valve or drainage tube and the scarring invoked by the cytokine response, the inventors have developed a shunt device and method of treatment for glaucoma that diverts aqueous humor from the anterior chamber to an epithelial-lined space. While the method and device have been successfully demonstrated with dogs, in which the shunt was implanted between the anterior chamber of the eye and the frontal sinus, the invention has application for the treatment of glaucoma in all species of animals, including humans, and to other epithelial-lined spaces besides the frontal sinus.
- The term “epithelial-lined space”, as used herein and in the claims includes epithelial and epithelial-lined spaces, including the frontal sinus, maxillary sinus, nasal sinus, other respiratory sinuses or spaces, subdural space, and meningeal cavity.
- Broadly, the invention provides a shunt for implantation between the anterior chamber of the eye and the epithelial-lined space through the frontal sinus bone of a patient for the treatment of glaucoma. The shunt includes a tube having a length sufficient to span the distance between the anterior chamber of the eye and the epithelial-lined space of the patient, the tube having an open anterior chamber end and a closed epithelial-lined space end, and a seal device associated with the tube between the anterior chamber and epithelial-lined space ends, for sealing a hole in the frontal sinus bone, and for anchoring the tube against movement from the frontal sinus bone. The shunt also includes a fluid pressure openable valve in the tube, located at or near the epithelial-lined space sinus end, allowing for controlled flow of aqueous humor through the tube when implanted.
- The invention also broadly provides a method of treating glaucoma in a patient, comprising (a) forming a hole from the exterior into the epithelial-lined space, for example in the frontal sinus bone, of the patient; (b) surgically implanting through the hole, between the anterior chamber and the epithelial-lined space, a shunt having a fluid pressure openable valve; and (c) draining aqueous humor from the anterior chamber through the shunt to the epithelial-lined space. The shunt preferably includes a tube having an open anterior chamber end and a closed epithelial-lined space end, and wherein the valve is located at the frontal sinus end, allowing for controlled flow of aqueous humor through the tube when implanted.
-
FIG. 1 illustrates the shunt of the present invention implanted in a dog, with portions of the eye being cut away to illustrate placement of the shunt between the anterior chamber and the frontal sinus; -
FIG. 2 is a sectional view of the shunt implanted in the eye, better illustrating the anterior chamber placement. -
FIG. 3 is a sectional view of the shunt threaded through the anchoring sealing device. -
FIG. 4 is a sectional view of the shunt showing the anchoring sealing device in place in the hole in the frontal sinus bone. -
FIG. 5 is a partial perspective view of the shunt showing the slit valve and the ligatures used to adjust and control flow of aqueous humor through the valve. -
FIG. 6 is a schematic side sectional view of a second embodiment of a shunt of the present invention, illustrating a drainage reservoir housing for alternate valve devices. -
FIG. 7 is an a schematic side sectional view of a third embodiment of a shunt of the present invention, illustrating a drainage reservoir for housing alternate valve devices, which drainage reservoir also functions as the sealing device. -
FIG. 8 is a perspective view, partially cut-away, showing a tapered nipple plug type valve within the reservoir chamber of eitherFIGS. 7 and 8 . -
FIG. 9 is a perspective view, partially cut-away, showing the tapered nipple plug valve ofFIG. 8 in the open position. -
FIG. 10 is a perspective view of the taper nipple plug valve unit ofFIGS. 8 and 9 . - The shunt of the present invention, shown generally at 10 in the Figures is shown as designed for implantation between the anterior chamber and the frontal sinus, however, the shunt has application for implantation to other epithelial-lined spaces, including the maxillary sinus, nasal sinus, other respiratory sinuses or spaces, subdural space, and meningeal cavity.
- The details of a first embodiment of the
shunt 10 are best shown inFIGS. 3-5 , while the placement of theshunt 10 in a dog is shown inFIGS. 1 and 2 . Theshunt 10 consists of atube 12, made of a biocompatible material such as silicone. The length of the tube required is dependent on the species, but is of sufficient length to reach the distance between theanterior chamber 14 and thefrontal sinus 16, through thefrontal sinus bone 18, of the given animal species. Thetube 12 thus has afrontal sinus end 20 and ananterior chamber end 22. Thetube 12 is threaded through asutureless sealing device 24, which seals around thehole 25 in thefrontal sinus bone 18. The sealingdevice 24 is located close to thefrontal sinus end 20 of thetube 12. This acts to hold thetube 12 in place as well as prevents it from kinking. Avalve device 26 is provided at or near thefrontal sinus end 20 of the tube 12 (i.e., when implanted the valve is on the sinus side of the frontal sinus bone). The sealingdevice 24 also functions to prevent serum and clots from exuding from the exposedbone 18 and from subcutaneous tissues within the frontal sinus and into thevalve device 26. InFIGS. 1 and 3 , thevalve device 26 is shown to be of a slit valve type, formed by constructing aslit 28 in thefrontal sinus end 20 of thetube 12 approximately parallel to the longitudinal axis of thetube 12. Thisfrontal sinus end 20 is inserted into thefrontal sinus 16 and held in place with the sealingcomponent 24, which straddles thefrontal sinus bone 18 and anchors the tube against movement in either direction. Thetube 12 is then tunnelled subcutaneously towards the eye and into theanterior chamber 14. Surgical implantation of theshunt 10 is more fully explained below. - The shunt will generally have a length ranging from 30 to 150 mm, and may be trimmed to length during surgery. However, the shunt can be made to fit any species of animal (including humans) by trimming any excess length from the
anterior chamber end 22. The shunt is generally formed from flexible, biocompatible materials such as silicone, glass, medical grade acrylics, plastic, or metal manufactured parts, with silicone or any similar biocompatible, flexible material being most preferred. One advantage of the present invention is that thetube 12 of theshunt 10 can be formed from tubing having internal and external diameters that can be varied according to the patient species together with the surgeon's preference and/or the surgeon's skill. The dimensions are affected by the space available in a particular patient's eye between the cornea and the lens. Thetube 12 should be sized so as to be fitted into such space in such a fashion that theanterior chamber end 22 does not contact the iris, lens or cornea. While not being limiting, exemplary dimensions for the shunt of the present invention for implantation in dogs, taking into account the ordinary skill of a surgeon, are as follows. For thetube portion 12, flexible tubing (such as silastic tubing) ranging from 0.25 to 0.64 mm inner diameters and 0.6 to 0.14 mm outer diameters with a wall thickness from 0.2 to 0.64 mm are optimal. - The method and shunt 10 of the present invention allows for the control of aqueous humor flow from the
valve device 26 by means of a simple adjustment procedure, explained more fully below. A major constraint of prior art glaucoma shunts, the control of intraocular pressure via fluid flow from valves, is addressed with the present invention in that the flow of aqueous humor is controlled by using an adjustable valve, or by associating a flow control device with a valve. As best shown inFIG. 5 , flow adjustment through theslit 28 is provided by means of one ormore ligature devices 30. Theligature devices 30 may be formed from O-rings, D-rings, C-clamps, sutures, or circumferential sutures formed of a biocompatible material, which are placed or tied around thetube 12 over and/or adjacent theslit 28. Theseligature devices 30 tighten theslit 28, allowing less fluid to escape from thetube 12 and drain from theanterior chamber 14. The addition or removal of theseligature devices 30 to control flow can be made by a simple skin incision above thefrontal sinus 16, which also allows for easy removal of the shunt 10 (more fully described below). Hydrostatic pressures of aqueous humor of glaucoma-affected patients can vary among species and idiotypically among patients. Also, rates of aqueous fluid of different species vary significantly. The easy adjustment of thevalve device 26 allows thisshunt 10 to be used in the treatment of various species, as well as each individual within a species. - The
slit 28 will generally be about 0.5 to 2.0 mm long, and oriented approximately parallel to the longitudinal axis of thetube 12. Theslit 28 is preferably perpendicular to the tangent of the tube wall. Variability in the length of the slit, the number of slits, the number of ligature devices and the positioning of ligature devices in relation to the slit provides flexibility sufficient to permit adjustment for use with various species, as well as various hydrostatic pressures of aqueous humor. - As shown in
FIG. 5 , theligature devices 30 around thetube 12, are mounted circumferentially around the longitudinal axis of theslit 28 and snug enough to slightly indent thetube 12 without disturbing the orientation of the slit. Theligature devices 30 are formed of a biocompatible material, with metal C-shaped clamps, and plastic, silicone, or rubber round O-rings, being most preferred. These preferred ligature devices are less prone to surgeon error than sutures in that they can be sized such that they do not excessively compress the valve walls and can be pre-placed at one or both ends of theslit 28. During surgical placement, theseligature devices 30 are slidably moved into variable positions along the length of theslit 28, and the intraocular pressure (fluid pressure indicative of glaucoma operative to open valve) is measured to ensure a desired intraocular pressure will open thevalve device 26. Multiple ligature devices, up to 3/mm, have been found to provide flexibility that allows the surgeon to finely adjust valve tension and aqueous flow rates through thevalve device 26. - The sealing
device 24 can take a variety of forms, such as a widened portion (not shown) of thetube 12, a widened reservoir plug as shown inFIG. 7 , or a spool-shaped plug type seal as shown inFIGS. 3 and 4 . It is functional to seal theshunt 10 against thehole 25 in thefrontal sinus bone 18, and to anchor the shunt against movement relative to thebone 18 once implanted. The sealing device also bends thetube 12 though an angle sufficient to ensure that thevalve device 26, when theshunt 10 is implanted, is wholly within the frontal sinus and maintained in the space (not abutting the frontal sinus epithelium. For most species of patients, an bending angle of 80 to 100° is desired, so as to maintain the most desired ingress and egress angle of the shunt between thefrontal sinus 16 and theanterior chamber 14. This best positions theshunt 10 and avoids narrowing of the lumen of thetube 12 or kinking of thetube 12. In one embodiment designed for dogs, an angle of about 90° was used. - The sealing device is most preferably a molded, spool-shaped (grommet-like) plug 32, attached to the
tube 12 and having ancentral bore 34 sized to fit snugly around thetube 12. The plug may be manufactured by carving a wax or wooden mold, positioning thetube 12 in the mold at the desired ingress and egress angles, flooding the mold with liquid silicone, allowing it to set and removing the plug from the mold. Theplug 32 has acentral portion 36 joined to and an upper flange or lip (anterior chamber facing) 38 and a lower flange or lip (frontal sinus facing) 40. Theflanges central portion 36. Biocompatible materials for the plug are silicone (a preferred embodiment) and rubber, plastic, glass, or metal components. At least thelower flange 40, which is frontal sinus facing, is made of a viscoelastic material such as silicone, to enable it to be compressed and forced through thehole 25 in thesinus bone 18. As mentioned above, theplug 32 bends thetube 12 though about an 80 to 100° angle. - The
shunt 10 should enter the anterior chamber 10-25 degrees anterior to the limbal plane to avoid contact with the iris, crystalline lens, or corneal endothelium. Thetrephine hole 25 of thefrontal sinus 16 is best situated approximately perpendicular to thefrontal bone 18. Thetube 12 should enter and leave the atplug 32 at about 90° (i.e., bend the tube through about 90°), but curve gently within thecentral bore 34 of theplug 32, to decrease the potential for occlusion of theshunt 10 by kinking thetube 12 or allowing trapping of fibrin clots within this turn of thetube 12. The frontal sinus plug 32 should be compressible to allow thelower flange 40, having a diameter slightly larger than the trephinedhole 25, to be introduced into the frontal sinus (preventing unintentional egression of the shunt 10), and providing pressure against the bony walls of the trephinedhole 25 to stop hemorrhage from thebone 18 and to stop fibrin and blood from collecting around thevalve device 26. - Without being limiting, in one embodiment of the shunt designed for dogs, the
center portion 36 has a diameter of about 0.25-1.5 mm, which is approximately equal to the bore dimensions of the trephinedhole 25, and approximately 0.1 mm shorter than the thickness of the bone 18 (1-2.5 mm), to create a tight sealing fit to prevent haemorrhage from thebone 18 that may drain onto thevalve device 26. The external diameter of theflanges tube 12, and at least twice the diameter of the trephinedhole 25 to prevent complete ingress into thefrontal sinus 16. - As indicated above, the shunt of the present invention, and its parts, are formed from biocompatible materials, that is materials which are biologically non-reactive and non-toxic to the patient. Examples are silicone (sialastic tubing), glass, medical grade plastic and some metals.
- Second and third embodiments of the
shunt 10 are shown inFIGS. 6-10 . InFIG. 6 , thevalve device 26 is shown to include adrainage reservoir 42 housing a valve element (not shown). InFIG. 7 , thedrainage reservoir 42 is shown to also function as the sealingdevice 24 in thefrontal bone 18. A variety of check valve types may be incorporated in these embodiments, such as the nipple plug type valve shown inFIGS. 7-10 , or a butterfly valve (not shown). Thereservoir 42 is shown in the figures to be formed from an aperturedupper plate 44, aclosed bottom plate 46, connected together by aside wall 48 which includes perforations such aslongitudinal slits 50 which allow fluid to drain from thereservoir 42. InFIG. 7 , thereservoir 42 is shown to include a widened sealingflange 52, to seal and anchor against thefrontal sinus bone 18. The nipple plug type valve components are best shown inFIG. 10 , to include anupper orifice plate 54 and alower nipple plug 56 operative to seal in theorifice plate 54. Theplate 54 and plug 56 are joined together in a normally closed position (shown inFIG. 8 ), by aspring member 58, having a tension such that the valve is fluid openable under predetermined pressures associated with glaucoma to allow fluid to flow through theorifice plate 54 and out theperforations 50. When implanted, once the pressure diminishes thenippled plug 56 will reseal against theorifice plate 54. - Method of Treatment of Glaucoma—Surgical Implantation and Testing
- Surgical implantation of the
shunt 10 in accordance with the present invention is described below, following aseptic preparation of the surgical field including the eye and skin of the patient and positioning the patient under an operating microscope. Over the ipsilateral frontal bone, the skin, subcutaneous tissues, and muscle over the zygomatic process of the frontal bone are incised. The incision should be long enough to expose the frontal bone over the frontal sinus (typically approx 1″ long and oriented rostrocaudally. The location of thefrontal sinus 16 can be confirmed by tapping the frontal bone of the zygomatic process with a solid object (such as a surgical instrument) to confirm a hollow sound. - A drilling device (such as a Jacob's chuck and Steinmann's pin—not shown), sized appropriately for the patient, is employed to make the
hole 25 in thebone 18 over thefrontal sinus 16, into thefrontal sinus 16 from the exterior. The size of thehole 25 will vary with patient and species, and is matched to the size of the sealingdevice 24. The sinus is visualized as a white cavity. - Patency of the
shunt 10 is confirmed by (i) cannulating the shunt (anterior chamber end 22) with a aqueous-fluid-filled syringe and needle (typically 27-30 ga.) assembly—not shown; (ii) flushing the aqueous fluid (e.g. sterile balanced slat solution) through theshunt 10 under pressure from the syringe; and (iii) visualizing fluid passing through thevalve device 26. - The
frontal sinus end 20 of theshunt 10 is placed within the trephinedhole 25 of the sinus and can be held in place by slight compression of the sealingdevice 24 and by the upper andlower flanges - An eyelid speculum, not shown, is then placed ipsilaterally on the eyelids to expose the conjunctival surface. A conjunctival incision is made from the limbus (junction of cornea, schlera, and conjuctiva) to the formix (reflexion of the conjuctiva under the eyelid) and extended through to the epischlera.
- An instrument such as pair of small forceps, not shown, is used to bluntly dissect a tunnel from the conjunctival incision to the frontal sinus incision (typically over the dorsal rim of the orbit to the original surgical dissection exposing the frontal sinus). When the tip of such instrument can be visualized it can be used to grasp the free end (anterior chamber end 22) of the shunt. The
shunt 10 is then drawn back through the tunnel through the conjunctival incision. Theshunt 10 is layed across the surface of the cornea and the length of the shunt is trimmed so as to adjust its length such that is rests approximately 1/4 of the vertical length of theanterior chamber 14. Theanterior chamber end 22 of the shunt is trimmed obliquely at 45 to 60 degrees with the bevel opening anteriorly. - A cutting device (e.g., 20 gauge disposable stilleto blade, not shown) is used to enter the
anterior chamber 14 at the limbus. The angle at which the blade enters the anterior chamber should be approximately 20° (theshunt 10 should enter theanterior chamber 14 at 10-25° anterior to the limbal plane to ensure that the shunt is positioned equal distance between the iris and the cornea to avoid contact between the shunt and the iris, crystal lens, or corneal endothelium). - Small forceps (e.g. tying forceps) are used to grasp the
anterior chamber end 22 of the shunt near the bevelled end, and theshunt 10 is inserted into theanterior chamber 14. Theshunt 10 is anchored to the sclera with, for example, nonabsorbable (monofilament) more than one (usually to or maximally (practically) three) sutures in a simple interrupted pattern. - The Tenon's capsule and conjunctiva are closed with, for example, simple interrupted sutures of small (7-0 to 10-0) monofilament absorbable sutures. The
frontal sinus end 20 of the shunt is withdrawn from thefrontal sinus 16 and monitored for flow of aqueous humor through thevalve device 26. When fluid flow through thevalve device 26 is confirmed, such flow is adjusted at thevalve device 26. In the case of a slit valve, the flow is adjusted with at least oneligature device 30 around or adjacent theslit 28 to maintain a desired intraocular pressure, which can be measured at the corneal surface with an applanation tonometer in the O.R. (normal for dog approximately 18 mm Hg). Thevalve device 26 is adjusted to open above this predetermined and known fluid pressure associated with glaucoma. The predetermined fluid pressure associated with glaucoma is known for other species, and the valve device can be adjusted accordingly for other species. - The
frontal sinus end 20 of theshunt 10 is then replaced into thefrontal sinus 16. Subcutaneous tissues are closed with, for example, small (3-0 to 6-0) monofilament absorbable sutures in a simple continuous pattern. The skin is subsequently closed with, for example, small (3-0 to 5-0) monofilament nonabsorbable suture in a simple interrupted pattern. - It is common with all intraocular shunts to become fibrin coated or occluded with fibrin shortly after surgery (within the first week post-surgery). The
shunt 10 of this invention can be flushed through thevalve device 26 by incising the skin, removing thefrontal sinus end 20, and back flushing an antifibrinolytic compound (e.g. tissue plasminogen activator (TPA)) retrograde through the shunt. Subsequent flushing of theshunt 10 with TPA or saline in the event of occlusion of the shunt is accomplished by exposing thefrontal sinus end 20 of theshunt 10, removing it from thesinus 16, and flushing the shunt retrograde. When flow is observed and the desired intraocular pressure is attained by adjusting thevalve device 26, e.g. adjusting theligature devices 30, thefrontal sinus end 20 of the shunt is then replaced, and the surgical site closed as described above. - In the event that the intraocular pressure is observed to be routinely less than the desired intraocular pressure, the
frontal sinus end 20 of theshunt 10 can be exposed and ligatures placed at various intervals along theslit 28 to attain the desired intraocular pressure. - A shunt of the present invention was designed for and successfully implanted into four dogs having glaucoma. The details of the implanted shunt were as follows:
- Tube and Slit Valve
-
- Inner Diameter 0.02″ (0.5 mm)
- Outer diameter 0.037″ (0.94 mm)
- Length of Tube (rough cut to be 100 mm) then tailored to each eye in the operating room so that it extended approximately 1/3 away across the anterior chamber of the eye.
- Slit—1 mm length
- # Ligatures—4—to maintain predetermined fluid pressure, adjusted in the operating room
- Hole in the Frontal sinus bone (diameter)—(2 mm)
Plug (Sealing Device) - Central Portion (that traversed the width of the bone)—(1.5 mm)
- Lower flange—2.5 mm
- Upper Flange—5 mm
- Length of Plug (Central Portion—traversing the bone)—3 mm
- These patients did not experience frontal sinus, subcutaneous, conjunctival or intraocular infections; fibrosis, haemorrhage, or other untoward complications. Each of the four patients was reoperated on within days of the first surgery to establish and verify shunt patency and operation and to demonstrate readjustment of the valves and retrograde flushing. Each patient was and is continually to be monitored for visual function and untoward side effects. All anti-glaucoma medications have been discontinued. Regular re-examination with tonometry, visual function testing, biomicroscopy and indirect ophthamoscopy has demonstrated maintenance of vision and desired intraocular pressures for period of up to 2 years post initial surgery.
- Advantages
- Generally, eyes inflicted with glaucoma build up protein in the aqueous humor. Prior art implanted drainage devices often become blocked with the protein, inhibiting fluid drainage from the eye. To correct this problem with prior art glaucoma treatment devices, an additional invasive surgery is needed to clean, remove, or replace the implant. The method and shunt of the present invention allows the correction to be made by a simple skin incision above the frontal sinus. The sealing
device 24 andanterior chamber end 22 of thetube 12 are removed from thefrontal sinus 16, flushed with sterile fluid, and reinserted. Further cleanings are not normally required. The fibrous tissue that collects around the shunt once implanted forms a tunnel from the sinus incision to theanterior chamber 14. If theshunt 10 needs to be replaced, the original can be removed through the sinus incision and a new device inserted through the tunnel created by the fibrous tissue. An extensive surgery is not required. - All publications mentioned in this specification are indicative of the level of skill in the art to which this invention pertains. To the extent they are consistent herewith, all publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. No admission is made that any cited reference constitutes prior art.
- Although the foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding it will be understood that certain changes and modifications may be made without departing from the scope or spirit of the invention as defined by the following claims.
-
- Cullen, C. L., Allen, A. L., & Grahn, B. H. 1998, “Anterior chamber to frontal sinus shunt for the diversion of aqueous humor: a pilot study in four normal dogs”, Veterinary Ophthalmology, vol. 1, pp. 31-9.
- Gal, M. A Novel Glaucoma Drainage Valve, 1999 [WWW document]. Proquest Digital Dissertations (visited 2002, Feb. 28). URL http://wwwlib.umi.com/dissertations/gateway
- Glaucoma Research Foundation (visited 2002, Mar. 11). Learn About Glaucoma [WWW document]. URL http://www.glaucoma.org/
- Moffett, D., Moffett, S., & Schauf, C. 1993, Human Physiology Foundations & Frontiers, 2nd edn, Mosby, St. Louis.
- U.S. Pat. Nos. 6,142,969 and 6,007,510 to Nigam. (Anamed, Inc.).
- U.S. Pat. Nos. 5,454,796 and Des. 356,867 to Krupin (Hood Laboratories).
Claims (22)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/515,999 US20050273033A1 (en) | 2002-05-29 | 2003-05-29 | Shunt and method treatment of glaucoma |
US12/190,211 US7947008B2 (en) | 2002-05-29 | 2008-08-12 | Shunt and method treatment of glaucoma |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38359902P | 2002-05-29 | 2002-05-29 | |
PCT/CA2003/000774 WO2003099175A1 (en) | 2002-05-29 | 2003-05-29 | A shunt and method treatment of glaucoma |
US10/515,999 US20050273033A1 (en) | 2002-05-29 | 2003-05-29 | Shunt and method treatment of glaucoma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/190,211 Continuation US7947008B2 (en) | 2002-05-29 | 2008-08-12 | Shunt and method treatment of glaucoma |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050273033A1 true US20050273033A1 (en) | 2005-12-08 |
Family
ID=29584589
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/515,999 Abandoned US20050273033A1 (en) | 2002-05-29 | 2003-05-29 | Shunt and method treatment of glaucoma |
US12/190,211 Expired - Fee Related US7947008B2 (en) | 2002-05-29 | 2008-08-12 | Shunt and method treatment of glaucoma |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/190,211 Expired - Fee Related US7947008B2 (en) | 2002-05-29 | 2008-08-12 | Shunt and method treatment of glaucoma |
Country Status (4)
Country | Link |
---|---|
US (2) | US20050273033A1 (en) |
AU (1) | AU2003233300A1 (en) |
CA (1) | CA2487733C (en) |
WO (1) | WO2003099175A1 (en) |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030229303A1 (en) * | 2002-03-22 | 2003-12-11 | Haffner David S. | Expandable glaucoma implant and methods of use |
US20060069340A1 (en) * | 2003-06-16 | 2006-03-30 | Solx, Inc. | Shunt for the treatment of glaucoma |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US7815592B2 (en) | 2003-11-14 | 2010-10-19 | Transcend Medical, Inc. | Ocular pressure regulation |
US20100280349A1 (en) * | 2009-05-04 | 2010-11-04 | Bruno Dacquay | Intraocular Pressure Sensor |
US20100286498A1 (en) * | 2009-05-07 | 2010-11-11 | Bruno Dacquay | Intraocular Pressure Sensor |
US20110071458A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Glaucoma Drainage Device with Pump |
WO2011034738A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Power generator for glaucoma drainage device |
US20110071505A1 (en) * | 2009-09-21 | 2011-03-24 | Matthew Rickard | Intraocular Pressure Sensor with External Pressure Compensation |
US20110071456A1 (en) * | 2009-09-21 | 2011-03-24 | Rickard Matthew J A | Lumen Clearing Valve For Glaucoma Drainage Device |
US20110071459A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Power Saving Glaucoma Drainage Device |
US20110238075A1 (en) * | 2009-12-23 | 2011-09-29 | Luke Clauson | Drug delivery devices and methods |
US8167939B2 (en) | 2009-01-28 | 2012-05-01 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8267882B2 (en) | 2008-03-05 | 2012-09-18 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8337509B2 (en) | 2007-11-20 | 2012-12-25 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8372026B2 (en) | 2007-09-24 | 2013-02-12 | Ivantis, Inc. | Ocular implant architectures |
US8425449B2 (en) | 2009-07-09 | 2013-04-23 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US8444588B2 (en) | 2003-05-05 | 2013-05-21 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US8579848B2 (en) | 2011-12-09 | 2013-11-12 | Alcon Research, Ltd. | Active drainage systems with pressure-driven valves and electronically-driven pump |
US8585631B2 (en) | 2011-10-18 | 2013-11-19 | Alcon Research, Ltd. | Active bimodal valve system for real-time IOP control |
US20130317412A1 (en) * | 2012-05-23 | 2013-11-28 | Bruno Dacquay | Flow Control For Treating A Medical Condition |
US8603024B2 (en) | 2011-12-12 | 2013-12-10 | Alcon Research, Ltd. | Glaucoma drainage devices including vario-stable valves and associated systems and methods |
US8617139B2 (en) | 2008-06-25 | 2013-12-31 | Transcend Medical, Inc. | Ocular implant with shape change capabilities |
JP2014501542A (en) * | 2010-10-08 | 2014-01-23 | シノプシス サージカル インコーポレイテッド | Implant devices, tools and methods for treatment of sinuses |
US8652085B2 (en) | 2012-07-02 | 2014-02-18 | Alcon Research, Ltd. | Reduction of gas escape in membrane actuators |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US8672870B2 (en) | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
US8721656B2 (en) | 2006-01-17 | 2014-05-13 | Transcend Medical, Inc. | Glaucoma treatment device |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US8753305B2 (en) | 2011-12-06 | 2014-06-17 | Alcon Research, Ltd. | Bubble-driven IOP control system |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8815278B2 (en) * | 2011-07-19 | 2014-08-26 | Abbott Cardiovascular Systems Inc. | Drug delivery device and method |
US8840578B2 (en) | 2011-12-09 | 2014-09-23 | Alcon Research, Ltd. | Multilayer membrane actuators |
US8986240B2 (en) | 2012-02-14 | 2015-03-24 | Alcon Research, Ltd. | Corrugated membrane actuators |
US8998838B2 (en) | 2012-03-29 | 2015-04-07 | Alcon Research, Ltd. | Adjustable valve for IOP control with reed valve |
US9072588B2 (en) | 2011-10-03 | 2015-07-07 | Alcon Research, Ltd. | Selectable varied control valve systems for IOP control systems |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9125721B2 (en) | 2011-12-13 | 2015-09-08 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven valves |
US9155653B2 (en) | 2012-02-14 | 2015-10-13 | Alcon Research, Ltd. | Pressure-driven membrane valve for pressure control system |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9226851B2 (en) | 2013-08-24 | 2016-01-05 | Novartis Ag | MEMS check valve chip and methods |
US9283114B2 (en) | 2013-08-24 | 2016-03-15 | Novartis Ag | Systems and methods for priming a microfluidic chamber |
US9283115B2 (en) | 2013-08-26 | 2016-03-15 | Novartis Ag | Passive to active staged drainage device |
US9289324B2 (en) | 2013-08-26 | 2016-03-22 | Novartis Ag | Externally adjustable passive drainage device |
US9295389B2 (en) | 2012-12-17 | 2016-03-29 | Novartis Ag | Systems and methods for priming an intraocular pressure sensor in an intraocular implant |
US9339187B2 (en) | 2011-12-15 | 2016-05-17 | Alcon Research, Ltd. | External pressure measurement system and method for an intraocular implant |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9492321B2 (en) | 2013-08-24 | 2016-11-15 | Novartis Ag | Bubble-free microfluidic valve systems and methods |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US9528633B2 (en) | 2012-12-17 | 2016-12-27 | Novartis Ag | MEMS check valve |
US9561350B2 (en) | 2013-01-25 | 2017-02-07 | Sinopsys Surgical, Inc. | Paranasal sinus access implant devices and related tools, methods and kits |
US9572712B2 (en) | 2012-12-17 | 2017-02-21 | Novartis Ag | Osmotically actuated fluidic valve |
US9572964B2 (en) | 2012-04-11 | 2017-02-21 | Sinapsys Surgical, Inc. | Implantation tools, tool assemblies, kits and methods |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9579234B2 (en) | 2009-10-23 | 2017-02-28 | Ivantis, Inc. | Ocular implant system and method |
US9603742B2 (en) | 2014-03-13 | 2017-03-28 | Novartis Ag | Remote magnetic driven flow system |
US9622910B2 (en) | 2011-12-12 | 2017-04-18 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven values |
US9655777B2 (en) | 2015-04-07 | 2017-05-23 | Novartis Ag | System and method for diagphragm pumping using heating element |
US9681983B2 (en) | 2014-03-13 | 2017-06-20 | Novartis Ag | Debris clearance system for an ocular implant |
US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US9700459B2 (en) | 2013-10-16 | 2017-07-11 | Sinopsys Surgical, Inc. | Apparatuses, tools and kits relating to fluid manipulation treatments of paranasal sinuses |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US20180263819A1 (en) * | 2017-03-17 | 2018-09-20 | W. L. Gore & Associates, Inc. | Glaucoma treatment systems and methods |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US10758408B1 (en) * | 2016-10-13 | 2020-09-01 | University Of South Florida | Tethered eye cannula and method of use |
US10898375B2 (en) | 2014-07-24 | 2021-01-26 | Sinopsys Surgical, Inc. | Paranasal sinus access implant devices and related products and methods |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11129972B2 (en) | 2017-09-20 | 2021-09-28 | Sinopsys Surgical, Inc. | Paranasal sinus fluid access implantation tools, assemblies, kits and methods |
WO2021247972A1 (en) * | 2020-06-04 | 2021-12-09 | The Board Of Regents Of The University Of Texas System | Eye shunt system and methods |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
US11540940B2 (en) | 2021-01-11 | 2023-01-03 | Alcon Inc. | Systems and methods for viscoelastic delivery |
US11617644B2 (en) | 2014-10-13 | 2023-04-04 | W. L. Gore & Associates, Inc. | Prosthetic valved conduit |
WO2023064487A1 (en) * | 2021-10-13 | 2023-04-20 | Shifamed Holdings, Llc | Systems and methods for delivering and deploying adjustable shunting systems |
US11678983B2 (en) | 2018-12-12 | 2023-06-20 | W. L. Gore & Associates, Inc. | Implantable component with socket |
US11744734B2 (en) | 2007-09-24 | 2023-09-05 | Alcon Inc. | Method of implanting an ocular implant |
USD1010123S1 (en) | 2020-06-04 | 2024-01-02 | The Board Of Regents Of The University Of Texas System | Forceps |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR054647A1 (en) | 2005-02-21 | 2007-07-11 | Maldonado Bas Arturo | DEVICE FOR WATER HUMOR DRAINAGE IN GLAUCOMA CASES |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US20120123316A1 (en) | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Intraocular shunts for placement in the intra-tenon's space |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
EP2043572B1 (en) * | 2006-06-30 | 2014-12-31 | Aquesys Inc. | Apparatus for relieving pressure in an organ |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US8758290B2 (en) | 2010-11-15 | 2014-06-24 | Aquesys, Inc. | Devices and methods for implanting a shunt in the suprachoroidal space |
DE102007004906A1 (en) | 2007-01-25 | 2008-07-31 | Universität Rostock | eye implant |
US8951221B2 (en) * | 2009-08-20 | 2015-02-10 | Grieshaber Ophthalmic Research Foundation | Method and device for the treatment of glaucoma |
US20160256317A1 (en) | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Methods for implanting intraocular shunts |
US8585629B2 (en) | 2010-11-15 | 2013-11-19 | Aquesys, Inc. | Systems for deploying intraocular shunts |
WO2012068115A2 (en) * | 2010-11-15 | 2012-05-24 | Aquesys, Inc. | Intraocular shunts and methods for placing an intraocular shunt in the intra-tenon's space |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US8852136B2 (en) | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US9610195B2 (en) | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
WO2014036437A1 (en) | 2012-08-30 | 2014-03-06 | Massachusetts Eye & Ear Infirmary | Ferromagnetic valves |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US9585790B2 (en) | 2013-11-14 | 2017-03-07 | Aquesys, Inc. | Intraocular shunt inserter |
US10201451B2 (en) | 2014-08-29 | 2019-02-12 | Camras Vision Inc. | Device and method for reducing intraocular pressure |
US10342702B2 (en) | 2014-08-29 | 2019-07-09 | Camras Vision Inc. | Apparatus and method for reducing intraocular pressure |
WO2016060538A1 (en) * | 2014-10-17 | 2016-04-21 | Manuel Humberto Gallardo Inzunza | Valve for compensating and regulating intraocular pressure |
US20180005167A1 (en) * | 2014-12-24 | 2018-01-04 | Swyft Inc. | System and a Method for Facilitating the Provision of Goods |
US20180110650A1 (en) | 2015-03-16 | 2018-04-26 | Jeannette M.A. da Silva Curiel | Method and Apparatus for Inserting an Implant in the Cornea of the Eye |
BR112017025859A2 (en) | 2015-06-03 | 2018-08-14 | Aquesys, Inc. | external ab intraocular shunt placement |
US10524958B2 (en) | 2015-09-30 | 2020-01-07 | Alievio, Inc. | Method and apparatus for reducing intraocular pressure |
WO2017210627A1 (en) | 2016-06-02 | 2017-12-07 | Aquesys, Inc. | Intraocular drug delivery |
US11166849B2 (en) | 2017-07-20 | 2021-11-09 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and methods for making and using same |
EP4218692A3 (en) | 2017-07-20 | 2023-09-06 | Shifamed Holdings, LLC | Adjustable flow glaucoma shunts and methods for making and using same |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
WO2021072317A1 (en) * | 2019-10-10 | 2021-04-15 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and associated systems and methods |
WO2021072315A1 (en) | 2019-10-10 | 2021-04-15 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and associated systems and methods |
US11529258B2 (en) | 2020-01-23 | 2022-12-20 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and associated systems and methods |
AU2021219845A1 (en) | 2020-02-14 | 2022-09-01 | Shifamed Holdings, Llc | Shunting systems with rotation-based flow control assemblies, and associated systems and methods |
EP4106695A4 (en) | 2020-02-18 | 2024-03-20 | Shifamed Holdings Llc | Adjustable flow glaucoma shunts having non-linearly arranged flow control elements, and associated systems and methods |
US11766355B2 (en) | 2020-03-19 | 2023-09-26 | Shifamed Holdings, Llc | Intraocular shunts with low-profile actuation elements and associated systems and methods |
CN115867237A (en) | 2020-04-16 | 2023-03-28 | 施菲姆德控股有限责任公司 | Adjustable glaucoma treatment devices and related systems and methods |
EP4281144A1 (en) | 2021-01-22 | 2023-11-29 | Shifamed Holdings, LLC | Adjustable shunting systems with plate assemblies, and associated systems and methods |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4037604A (en) * | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4554918A (en) * | 1982-07-28 | 1985-11-26 | White Thomas C | Ocular pressure relief device |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
US5127901A (en) * | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5326345A (en) * | 1991-08-14 | 1994-07-05 | Price Jr Francis W | Eye filtration prostheses |
US5338291A (en) * | 1993-02-03 | 1994-08-16 | Pudenz-Schulte Medical Research Corporation | Glaucoma shunt and method for draining aqueous humor |
USD356867S (en) * | 1993-03-10 | 1995-03-28 | Hood Laboratories | Device for controlling intraocular fluid pressure |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US5810761A (en) * | 1997-02-26 | 1998-09-22 | Biomedica Mexicana, S.A. De C.V. | Intraventricular pressure control device |
US6007510A (en) * | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
US6142969A (en) * | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
US6283934B1 (en) * | 1996-09-18 | 2001-09-04 | Sinu Shunt A/S | Device for the treatment of hydrocephalus |
US6454794B1 (en) * | 1996-08-13 | 2002-09-24 | Heartstent Corporation | Coronary bypass implant |
US20020156413A1 (en) * | 1999-04-27 | 2002-10-24 | Stuart K. Williams | Glaucoma shunt and a method of making and surgically implanting the same |
US6510600B2 (en) * | 1997-11-20 | 2003-01-28 | Optonol, Ltd. | Method for manufacturing a flow regulating implant |
US20030055372A1 (en) * | 1999-04-26 | 2003-03-20 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US20030135149A1 (en) * | 2002-01-13 | 2003-07-17 | Cheryl Cullen | Sinus valved glaucoma shunt |
US6666841B2 (en) * | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3672981D1 (en) * | 1985-11-27 | 1990-08-30 | Thomas C White | TISSUE-IMPLANTABLE LIQUID DISTRIBUTION DEVICE. |
US5346464A (en) * | 1992-03-10 | 1994-09-13 | Camras Carl B | Method and apparatus for reducing intraocular pressure |
MXPA01010832A (en) | 1999-04-26 | 2003-06-30 | Gmp Vision Solutions Inc | Shunt device and method for treating glaucoma. |
-
2003
- 2003-05-29 CA CA2487733A patent/CA2487733C/en not_active Expired - Fee Related
- 2003-05-29 WO PCT/CA2003/000774 patent/WO2003099175A1/en not_active Application Discontinuation
- 2003-05-29 US US10/515,999 patent/US20050273033A1/en not_active Abandoned
- 2003-05-29 AU AU2003233300A patent/AU2003233300A1/en not_active Abandoned
-
2008
- 2008-08-12 US US12/190,211 patent/US7947008B2/en not_active Expired - Fee Related
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3788327A (en) * | 1971-03-30 | 1974-01-29 | H Donowitz | Surgical implant device |
US4037604A (en) * | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4402681A (en) * | 1980-08-23 | 1983-09-06 | Haas Joseph S | Artificial implant valve for the regulation of intraocular pressure |
US4554918A (en) * | 1982-07-28 | 1985-11-26 | White Thomas C | Ocular pressure relief device |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
US5127901A (en) * | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US5326345A (en) * | 1991-08-14 | 1994-07-05 | Price Jr Francis W | Eye filtration prostheses |
US5338291A (en) * | 1993-02-03 | 1994-08-16 | Pudenz-Schulte Medical Research Corporation | Glaucoma shunt and method for draining aqueous humor |
USD356867S (en) * | 1993-03-10 | 1995-03-28 | Hood Laboratories | Device for controlling intraocular fluid pressure |
US6454794B1 (en) * | 1996-08-13 | 2002-09-24 | Heartstent Corporation | Coronary bypass implant |
US6283934B1 (en) * | 1996-09-18 | 2001-09-04 | Sinu Shunt A/S | Device for the treatment of hydrocephalus |
US6007510A (en) * | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
US6142969A (en) * | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
US5810761A (en) * | 1997-02-26 | 1998-09-22 | Biomedica Mexicana, S.A. De C.V. | Intraventricular pressure control device |
US6510600B2 (en) * | 1997-11-20 | 2003-01-28 | Optonol, Ltd. | Method for manufacturing a flow regulating implant |
US20030055372A1 (en) * | 1999-04-26 | 2003-03-20 | Lynch Mary G. | Shunt device and method for treating glaucoma |
US20020156413A1 (en) * | 1999-04-27 | 2002-10-24 | Stuart K. Williams | Glaucoma shunt and a method of making and surgically implanting the same |
US6666841B2 (en) * | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
US20030135149A1 (en) * | 2002-01-13 | 2003-07-17 | Cheryl Cullen | Sinus valved glaucoma shunt |
Cited By (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492320B2 (en) | 1999-04-26 | 2016-11-15 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9827143B2 (en) | 1999-04-26 | 2017-11-28 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US10568762B2 (en) | 1999-04-26 | 2020-02-25 | Glaukos Corporation | Stent for treating ocular disorders |
US10492950B2 (en) | 1999-04-26 | 2019-12-03 | Glaukos Corporation | Shunt device and method for treating ocular disorders |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US10406029B2 (en) | 2001-04-07 | 2019-09-10 | Glaukos Corporation | Ocular system with anchoring implant and therapeutic agent |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US20030229303A1 (en) * | 2002-03-22 | 2003-12-11 | Haffner David S. | Expandable glaucoma implant and methods of use |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US9844462B2 (en) | 2003-05-05 | 2017-12-19 | Novartis Ag | Internal shunt and method for treating glaucoma |
US8444588B2 (en) | 2003-05-05 | 2013-05-21 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US8945038B2 (en) | 2003-05-05 | 2015-02-03 | Transcend Medical, Inc. | Internal shunt and method for treating glaucoma |
US20060069340A1 (en) * | 2003-06-16 | 2006-03-30 | Solx, Inc. | Shunt for the treatment of glaucoma |
US8808220B2 (en) | 2003-11-14 | 2014-08-19 | Transcend Medical, Inc. | Ocular pressure regulation |
US8771218B2 (en) | 2003-11-14 | 2014-07-08 | Transcend Medical, Inc. | Ocular pressure regulation |
US8728021B2 (en) | 2003-11-14 | 2014-05-20 | Transcend Medical, Inc. | Ocular pressure regulation |
US8758289B2 (en) | 2003-11-14 | 2014-06-24 | Transcend Medical, Inc. | Ocular pressure regulation |
US7815592B2 (en) | 2003-11-14 | 2010-10-19 | Transcend Medical, Inc. | Ocular pressure regulation |
US10226380B2 (en) | 2003-11-14 | 2019-03-12 | Novartis Ag | Ocular pressure regulation |
US8486000B2 (en) | 2003-11-14 | 2013-07-16 | Transcend Medical, Inc. | Ocular pressure regulation |
US8128588B2 (en) | 2003-11-14 | 2012-03-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US9351873B2 (en) | 2003-11-14 | 2016-05-31 | Transcend Medical, Inc. | Ocular pressure regulation |
US7850638B2 (en) | 2003-11-14 | 2010-12-14 | Transcend Medical, Inc. | Ocular pressure regulation |
US9084662B2 (en) | 2006-01-17 | 2015-07-21 | Transcend Medical, Inc. | Drug delivery treatment device |
US9398977B2 (en) | 2006-01-17 | 2016-07-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US9421130B2 (en) | 2006-01-17 | 2016-08-23 | Novartis Ag. | Glaucoma treatment device |
US8814819B2 (en) | 2006-01-17 | 2014-08-26 | Transcend Medical, Inc. | Glaucoma treatment device |
US10905590B2 (en) | 2006-01-17 | 2021-02-02 | Alcon Inc. | Glaucoma treatment device |
US8801649B2 (en) | 2006-01-17 | 2014-08-12 | Transcend Medical, Inc. | Glaucoma treatment device |
US11786402B2 (en) | 2006-01-17 | 2023-10-17 | Alcon Inc. | Glaucoma treatment device |
US9668917B2 (en) | 2006-01-17 | 2017-06-06 | Novartis Ag | Drug delivery treatment device |
US8734378B2 (en) | 2006-01-17 | 2014-05-27 | Transcend Medical, Inc. | Glaucoma treatment device |
US9789000B2 (en) | 2006-01-17 | 2017-10-17 | Novartis Ag | Glaucoma treatment device |
US8721656B2 (en) | 2006-01-17 | 2014-05-13 | Transcend Medical, Inc. | Glaucoma treatment device |
US8672870B2 (en) | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
US9585789B2 (en) | 2007-07-17 | 2017-03-07 | Novartis Ag | Ocular implant with hydrogel expansion capabilities |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US8414518B2 (en) | 2007-09-24 | 2013-04-09 | Ivantis, Inc. | Glaucoma treatment method |
US9402767B2 (en) | 2007-09-24 | 2016-08-02 | Ivantis, Inc. | Ocular implant architectures |
US8372026B2 (en) | 2007-09-24 | 2013-02-12 | Ivantis, Inc. | Ocular implant architectures |
US9039650B2 (en) | 2007-09-24 | 2015-05-26 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US11744734B2 (en) | 2007-09-24 | 2023-09-05 | Alcon Inc. | Method of implanting an ocular implant |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US8961447B2 (en) | 2007-09-24 | 2015-02-24 | Ivantis, Inc. | Glaucoma treatment method |
US8282592B2 (en) | 2007-09-24 | 2012-10-09 | Ivantis, Inc. | Glaucoma treatment method |
US9610196B2 (en) | 2007-09-24 | 2017-04-04 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US9050169B2 (en) | 2007-11-20 | 2015-06-09 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8551166B2 (en) | 2007-11-20 | 2013-10-08 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9226852B2 (en) | 2007-11-20 | 2016-01-05 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8337509B2 (en) | 2007-11-20 | 2012-12-25 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US9351874B2 (en) | 2007-11-20 | 2016-05-31 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US9693902B2 (en) | 2008-03-05 | 2017-07-04 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8529494B2 (en) | 2008-03-05 | 2013-09-10 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US10537474B2 (en) | 2008-03-05 | 2020-01-21 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US9066783B2 (en) | 2008-03-05 | 2015-06-30 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US8267882B2 (en) | 2008-03-05 | 2012-09-18 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
US11504275B2 (en) | 2008-03-05 | 2022-11-22 | Alcon Inc. | Methods and apparatus for treating glaucoma |
US8617139B2 (en) | 2008-06-25 | 2013-12-31 | Transcend Medical, Inc. | Ocular implant with shape change capabilities |
US10016301B2 (en) | 2008-06-25 | 2018-07-10 | Novartis Ag | Ocular implant with shape change capabilities |
US11839571B2 (en) | 2009-01-28 | 2023-12-12 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8172899B2 (en) | 2009-01-28 | 2012-05-08 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8262726B2 (en) | 2009-01-28 | 2012-09-11 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8167939B2 (en) | 2009-01-28 | 2012-05-01 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8377122B2 (en) | 2009-01-28 | 2013-02-19 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US10531983B2 (en) | 2009-01-28 | 2020-01-14 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US9763828B2 (en) | 2009-01-28 | 2017-09-19 | Novartis Ag | Ocular implant with stiffness qualities, methods of implantation and system |
US11344448B2 (en) | 2009-01-28 | 2022-05-31 | Alcon Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8574294B2 (en) | 2009-01-28 | 2013-11-05 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
US8182435B2 (en) | 2009-05-04 | 2012-05-22 | Alcon Research, Ltd. | Intraocular pressure sensor |
US20100280349A1 (en) * | 2009-05-04 | 2010-11-04 | Bruno Dacquay | Intraocular Pressure Sensor |
US20100286498A1 (en) * | 2009-05-07 | 2010-11-11 | Bruno Dacquay | Intraocular Pressure Sensor |
US8123687B2 (en) | 2009-05-07 | 2012-02-28 | Alcon Research, Ltd. | Intraocular pressure sensor |
US8425449B2 (en) | 2009-07-09 | 2013-04-23 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US11596546B2 (en) | 2009-07-09 | 2023-03-07 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US9211213B2 (en) | 2009-07-09 | 2015-12-15 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US11918514B2 (en) | 2009-07-09 | 2024-03-05 | Alcon Inc. | Single operator device for delivering an ocular implant |
US10492949B2 (en) | 2009-07-09 | 2019-12-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US11464675B2 (en) | 2009-07-09 | 2022-10-11 | Alcon Inc. | Single operator device for delivering an ocular implant |
US10406025B2 (en) | 2009-07-09 | 2019-09-10 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US9693899B2 (en) | 2009-07-09 | 2017-07-04 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
US20110071459A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Power Saving Glaucoma Drainage Device |
WO2011034738A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Power generator for glaucoma drainage device |
US20110071456A1 (en) * | 2009-09-21 | 2011-03-24 | Rickard Matthew J A | Lumen Clearing Valve For Glaucoma Drainage Device |
US9615970B2 (en) | 2009-09-21 | 2017-04-11 | Alcon Research, Ltd. | Intraocular pressure sensor with external pressure compensation |
US8545431B2 (en) | 2009-09-21 | 2013-10-01 | Alcon Research, Ltd. | Lumen clearing valve for glaucoma drainage device |
US8419673B2 (en) | 2009-09-21 | 2013-04-16 | Alcon Research, Ltd. | Glaucoma drainage device with pump |
US20110071505A1 (en) * | 2009-09-21 | 2011-03-24 | Matthew Rickard | Intraocular Pressure Sensor with External Pressure Compensation |
US8721580B2 (en) | 2009-09-21 | 2014-05-13 | Alcon Research, Ltd. | Power saving glaucoma drainage device |
US8808224B2 (en) | 2009-09-21 | 2014-08-19 | Alcon Research, Ltd. | Glaucoma drainage device with pump |
US20110071458A1 (en) * | 2009-09-21 | 2011-03-24 | Alcon Research, Ltd. | Glaucoma Drainage Device with Pump |
US8257295B2 (en) | 2009-09-21 | 2012-09-04 | Alcon Research, Ltd. | Intraocular pressure sensor with external pressure compensation |
US9579234B2 (en) | 2009-10-23 | 2017-02-28 | Ivantis, Inc. | Ocular implant system and method |
US9549846B2 (en) | 2009-12-23 | 2017-01-24 | Novartis Ag | Drug delivery devices and methods |
US8529492B2 (en) * | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US9089392B2 (en) | 2009-12-23 | 2015-07-28 | Transcend Medical, Inc. | Drug delivery devices and methods |
US20110238075A1 (en) * | 2009-12-23 | 2011-09-29 | Luke Clauson | Drug delivery devices and methods |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US10940297B2 (en) | 2010-10-08 | 2021-03-09 | Sinopsys Surgical, Inc. | Method for providing access to a paranasal sinus |
US10035004B2 (en) | 2010-10-08 | 2018-07-31 | Sinopsys Surgical, Inc. | Implant device, tool, and methods relating to treatment of paranasal sinuses |
JP2014501542A (en) * | 2010-10-08 | 2014-01-23 | シノプシス サージカル インコーポレイテッド | Implant devices, tools and methods for treatment of sinuses |
US9308358B2 (en) | 2010-10-08 | 2016-04-12 | Sinopsys Surgical, Inc. | Implant device, tool, and methods relating to treatment of paranasal sinuses |
US9901721B2 (en) | 2010-10-08 | 2018-02-27 | Sinopsys Surgical, Inc. | Method for delivery of treatment formulation to paranasal sinus |
US11110256B2 (en) | 2010-10-08 | 2021-09-07 | Sinopsys Surgical, Inc. | Kit for treatment of sinusitis |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US9155655B2 (en) | 2011-06-14 | 2015-10-13 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US10363168B2 (en) | 2011-06-14 | 2019-07-30 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US10307292B2 (en) | 2011-07-18 | 2019-06-04 | Mor Research Applications Ltd | Device for adjusting the intraocular pressure |
US9474832B2 (en) | 2011-07-19 | 2016-10-25 | Abbott Cardiovascular Systems Inc. | Drug delivery device and method |
US8815278B2 (en) * | 2011-07-19 | 2014-08-26 | Abbott Cardiovascular Systems Inc. | Drug delivery device and method |
US9072588B2 (en) | 2011-10-03 | 2015-07-07 | Alcon Research, Ltd. | Selectable varied control valve systems for IOP control systems |
US8585631B2 (en) | 2011-10-18 | 2013-11-19 | Alcon Research, Ltd. | Active bimodal valve system for real-time IOP control |
US8753305B2 (en) | 2011-12-06 | 2014-06-17 | Alcon Research, Ltd. | Bubble-driven IOP control system |
US8579848B2 (en) | 2011-12-09 | 2013-11-12 | Alcon Research, Ltd. | Active drainage systems with pressure-driven valves and electronically-driven pump |
US8840578B2 (en) | 2011-12-09 | 2014-09-23 | Alcon Research, Ltd. | Multilayer membrane actuators |
US8603024B2 (en) | 2011-12-12 | 2013-12-10 | Alcon Research, Ltd. | Glaucoma drainage devices including vario-stable valves and associated systems and methods |
US9622910B2 (en) | 2011-12-12 | 2017-04-18 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven values |
US9125721B2 (en) | 2011-12-13 | 2015-09-08 | Alcon Research, Ltd. | Active drainage systems with dual-input pressure-driven valves |
US9339187B2 (en) | 2011-12-15 | 2016-05-17 | Alcon Research, Ltd. | External pressure measurement system and method for an intraocular implant |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9931243B2 (en) | 2011-12-19 | 2018-04-03 | Ivantis, Inc. | Delivering ocular implants into the eye |
US11135088B2 (en) | 2011-12-19 | 2021-10-05 | Ivantis Inc. | Delivering ocular implants into the eye |
US9066750B2 (en) | 2011-12-19 | 2015-06-30 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9155653B2 (en) | 2012-02-14 | 2015-10-13 | Alcon Research, Ltd. | Pressure-driven membrane valve for pressure control system |
US8986240B2 (en) | 2012-02-14 | 2015-03-24 | Alcon Research, Ltd. | Corrugated membrane actuators |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11944573B2 (en) | 2012-03-26 | 2024-04-02 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US8998838B2 (en) | 2012-03-29 | 2015-04-07 | Alcon Research, Ltd. | Adjustable valve for IOP control with reed valve |
US9572964B2 (en) | 2012-04-11 | 2017-02-21 | Sinapsys Surgical, Inc. | Implantation tools, tool assemblies, kits and methods |
US11026836B2 (en) | 2012-04-18 | 2021-06-08 | Ivantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9155656B2 (en) | 2012-04-24 | 2015-10-13 | Transcend Medical, Inc. | Delivery system for ocular implant |
US9907697B2 (en) | 2012-04-24 | 2018-03-06 | Novartis Ag | Delivery system for ocular implant |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US10912676B2 (en) | 2012-04-24 | 2021-02-09 | Alcon Inc. | Delivery system for ocular implant |
US20130317412A1 (en) * | 2012-05-23 | 2013-11-28 | Bruno Dacquay | Flow Control For Treating A Medical Condition |
US8652085B2 (en) | 2012-07-02 | 2014-02-18 | Alcon Research, Ltd. | Reduction of gas escape in membrane actuators |
US9480598B2 (en) | 2012-09-17 | 2016-11-01 | Novartis Ag | Expanding ocular implant devices and methods |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US11712369B2 (en) | 2012-11-28 | 2023-08-01 | Alcon Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9295389B2 (en) | 2012-12-17 | 2016-03-29 | Novartis Ag | Systems and methods for priming an intraocular pressure sensor in an intraocular implant |
US9572712B2 (en) | 2012-12-17 | 2017-02-21 | Novartis Ag | Osmotically actuated fluidic valve |
US9528633B2 (en) | 2012-12-17 | 2016-12-27 | Novartis Ag | MEMS check valve |
US9561350B2 (en) | 2013-01-25 | 2017-02-07 | Sinopsys Surgical, Inc. | Paranasal sinus access implant devices and related tools, methods and kits |
US11559430B2 (en) | 2013-03-15 | 2023-01-24 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
US9226851B2 (en) | 2013-08-24 | 2016-01-05 | Novartis Ag | MEMS check valve chip and methods |
US9492321B2 (en) | 2013-08-24 | 2016-11-15 | Novartis Ag | Bubble-free microfluidic valve systems and methods |
US9283114B2 (en) | 2013-08-24 | 2016-03-15 | Novartis Ag | Systems and methods for priming a microfluidic chamber |
US9289324B2 (en) | 2013-08-26 | 2016-03-22 | Novartis Ag | Externally adjustable passive drainage device |
US9283115B2 (en) | 2013-08-26 | 2016-03-15 | Novartis Ag | Passive to active staged drainage device |
US9700459B2 (en) | 2013-10-16 | 2017-07-11 | Sinopsys Surgical, Inc. | Apparatuses, tools and kits relating to fluid manipulation treatments of paranasal sinuses |
US9681983B2 (en) | 2014-03-13 | 2017-06-20 | Novartis Ag | Debris clearance system for an ocular implant |
US9603742B2 (en) | 2014-03-13 | 2017-03-28 | Novartis Ag | Remote magnetic driven flow system |
US10959941B2 (en) | 2014-05-29 | 2021-03-30 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US10898375B2 (en) | 2014-07-24 | 2021-01-26 | Sinopsys Surgical, Inc. | Paranasal sinus access implant devices and related products and methods |
US11617644B2 (en) | 2014-10-13 | 2023-04-04 | W. L. Gore & Associates, Inc. | Prosthetic valved conduit |
US9655777B2 (en) | 2015-04-07 | 2017-05-23 | Novartis Ag | System and method for diagphragm pumping using heating element |
US11197779B2 (en) | 2015-08-14 | 2021-12-14 | Ivantis, Inc. | Ocular implant with pressure sensor and delivery system |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
US10758408B1 (en) * | 2016-10-13 | 2020-09-01 | University Of South Florida | Tethered eye cannula and method of use |
US11351058B2 (en) * | 2017-03-17 | 2022-06-07 | W. L. Gore & Associates, Inc. | Glaucoma treatment systems and methods |
US11406533B2 (en) | 2017-03-17 | 2022-08-09 | W. L. Gore & Associates, Inc. | Integrated aqueous shunt for glaucoma treatment |
US11523940B2 (en) | 2017-03-17 | 2022-12-13 | W. L. Gore & Associates, Inc. | Delivery aids for glaucoma shunts |
US20180263819A1 (en) * | 2017-03-17 | 2018-09-20 | W. L. Gore & Associates, Inc. | Glaucoma treatment systems and methods |
US11129972B2 (en) | 2017-09-20 | 2021-09-28 | Sinopsys Surgical, Inc. | Paranasal sinus fluid access implantation tools, assemblies, kits and methods |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11678983B2 (en) | 2018-12-12 | 2023-06-20 | W. L. Gore & Associates, Inc. | Implantable component with socket |
USD1010123S1 (en) | 2020-06-04 | 2024-01-02 | The Board Of Regents Of The University Of Texas System | Forceps |
WO2021247972A1 (en) * | 2020-06-04 | 2021-12-09 | The Board Of Regents Of The University Of Texas System | Eye shunt system and methods |
USD1022199S1 (en) | 2020-06-04 | 2024-04-09 | The Board Of Regents Of The University Of Texas System | Forceps |
US11540940B2 (en) | 2021-01-11 | 2023-01-03 | Alcon Inc. | Systems and methods for viscoelastic delivery |
WO2023064487A1 (en) * | 2021-10-13 | 2023-04-20 | Shifamed Holdings, Llc | Systems and methods for delivering and deploying adjustable shunting systems |
Also Published As
Publication number | Publication date |
---|---|
US20090036818A1 (en) | 2009-02-05 |
WO2003099175A1 (en) | 2003-12-04 |
CA2487733A1 (en) | 2003-12-04 |
AU2003233300A1 (en) | 2003-12-12 |
US7947008B2 (en) | 2011-05-24 |
CA2487733C (en) | 2011-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7947008B2 (en) | Shunt and method treatment of glaucoma | |
US10828473B2 (en) | Ocular implant delivery system and methods thereof | |
US10485702B2 (en) | System and method for treating an ocular disorder | |
MXPA05000807A (en) | Uveoscleral drainage device. | |
US10952897B1 (en) | Eye implant devices and method and device for implanting such devices for treatment of glaucoma | |
AU2012201744B2 (en) | Apparatus and method for treating ocular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC., CANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAHN, BRUCE HAROLD;STOREY, ERIC SHAD;STILLING, DENISE SHARON;REEL/FRAME:016689/0096;SIGNING DATES FROM 20030807 TO 20030812 |
|
AS | Assignment |
Owner name: UNIVERSITY OF SASKATCHEWAN, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES, INC.;REEL/FRAME:017763/0570 Effective date: 20060406 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |